Eli Lilly stock stalls near $1,140 as Foundayo grabs 30% of new obesity-drug patients
Covered by 1 source · 1 article
Eli Lilly stock presents conflicting signals across timeframes. The daily chart shows cooling, while the hourly hints at stabilization. Meanwhile, Berenberg upgraded LLY on obesity drug strength, as Foundayo captured over 30% of new U.S. or…
Covered by